Enhanced Radiation Therapy Systems through Synergistic Combinations
Legal Citation
Summary of the Inventive Concept
The inventive concept integrates the patented alpha-emitter radiation therapy with distinct technologies, such as AI, IoT, blockchain, and new materials, to create more effective and personalized radiation therapy systems.
Background and Problem Solved
The original patent disclosed an implantable radiation source with combined alpha and non-alpha radiation. However, this invention had limitations in terms of radiation intensity adjustment, patient data management, and radiation absorption. The new inventive concept addresses these limitations by introducing synergistic combinations of alpha-emitter radiation therapy with AI, IoT, blockchain, and new materials.
Detailed Description of the Inventive Concept
The new inventive concept comprises four synergistic combinations: (1) AI-controlled beta radiation source, which adjusts radiation intensity based on real-time tumor imaging data; (2) IoT-enabled temperature sensing, which monitors tumor temperature and adjusts alpha-emitting radiation intensity; (3) blockchain-secured patient data management system, which tracks and verifies patient treatment history and radiation exposure; and (4) nanomaterial-enhanced coating, which enhances radiation absorption and reduces systemic alpha radiation.
Novelty and Inventive Step
The new inventive concept introduces non-obvious synergistic combinations of alpha-emitter radiation therapy with distinct technologies, which provide more effective and personalized radiation therapy systems. The inventive step lies in the integration of these technologies to create a more powerful system.
Alternative Embodiments and Variations
Alternative embodiments may include the use of other AI algorithms, IoT sensors, blockchain platforms, or nanomaterials. Variations may include different types of radiation therapy, such as brachytherapy or external beam radiation therapy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the radiation therapy market, particularly in the areas of cancer treatment and personalized medicine. The target industries include hospitals, cancer treatment centers, and medical device manufacturers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Radiation therapy and medical device technologies, specifically focused on targeted radiation sources for cancer treatment, requiring expertise in radioisotope engineering, medical imaging, and therapeutic device design
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical physicist with advanced degrees, expertise in radiation therapy technologies, understanding of alpha and beta radiation principles, and familiarity with emerging medical technology integration strategies
Obviousness Rationale
A person having ordinary skill would recognize that the PTD represents predictable combinations of known radiation therapy technologies with emerging digital and materials technologies. The fundamental alpha radiation source from the source patent provides a clear foundation for integrating advanced control and monitoring systems. The variations represent logical extensions of existing radiation therapy technological approaches using standard engineering design techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,803 |
|---|---|
| Title | Diffusing alpha-emitter radiation therapy with enhanced beta treatment |
| Assignee(s) | Alpha Tau Medical Ltd |